Patient characteristics
| Characteristics . | Patients (N = 18) . |
|---|---|
| Age, y | |
| Median (range) | 44 (17-67) |
| Distribution, n (%) | |
| 15-39 | 7 (38.9) |
| 40-49 | 4 (22.2) |
| 50-59 | 4 (22.2) |
| 60-69 | 3 (16.7) |
| Sex, n (%) | |
| Male | 9 (50.0) |
| Female | 9 (50.0) |
| Race, n (%) | |
| White | 15 (83.3) |
| Black | 1 (5.6) |
| Asian | 1 (5.6) |
| Other or unreported | 1 (5.6) |
| Cytogenetics risk, n (%) | |
| Adverse∗ | 9 (50) |
| Ph+ | 6 (33.3) |
| Therapy before transplantation, n (%) | |
| Median lines of therapy (range) | 2 (1-5) |
| ASPNase-containing regimen | 6 (33.3) |
| Blinatumomab | 8 (44.4) |
| INO | 3 (16.7) |
| CAR T-cell therapy | 2 (11.1) |
| Allo-HCT | 1 (5.6) |
| Disease status before HCT, n (%) | |
| CR1 | 14 (77.8) |
| CR2 | 3 (16.7) |
| CR3 or more | 1 (5.6) |
| HCT-CI, n (%) | |
| 0 | 1 (5.6) |
| 1-2 | 7 (38.9) |
| ≥3 | 10 (55.6) |
| Donor type, n (%) | |
| Matched sibling | 2 (11.1) |
| Haploidentical | 3 (16.7) |
| Matched unrelated | 12 (66.7) |
| Cord blood | 1 (5.6) |
| Donor source, n (%) | |
| Bone marrow | 5 (27.8) |
| Peripheral blood | 12 (66.7) |
| Cord blood | 1 (5.6) |
| Conditioning regimen, n (%) | |
| MAC | 5 (27.8) |
| Busulfan based | 1 (5.6) |
| Other + TBI | 4 (22.2) |
| RIC | 13 (72.2) |
| Busulfan based | 2 (11.1) |
| Melphalan based | 8 (44.4) |
| Other + TBI | 3 (16.7) |
| ATG use | 6 (33.3) |
| GVHD prophylaxis regimen, n (%) | |
| CNI + MTX | 12 (66.7) |
| CNI + MMF | 2 (11.1) |
| PTCy | 4 (22.2) |
| MRD status | |
| MRD+ before HCT | 4 (22.2) |
| MRD+ after HCT | 1 (5.6) |
| MRD+ before and after HCT | 1 (5.6) |
| MRD− either before or after HCT | 12 (66.7) |
| Characteristics . | Patients (N = 18) . |
|---|---|
| Age, y | |
| Median (range) | 44 (17-67) |
| Distribution, n (%) | |
| 15-39 | 7 (38.9) |
| 40-49 | 4 (22.2) |
| 50-59 | 4 (22.2) |
| 60-69 | 3 (16.7) |
| Sex, n (%) | |
| Male | 9 (50.0) |
| Female | 9 (50.0) |
| Race, n (%) | |
| White | 15 (83.3) |
| Black | 1 (5.6) |
| Asian | 1 (5.6) |
| Other or unreported | 1 (5.6) |
| Cytogenetics risk, n (%) | |
| Adverse∗ | 9 (50) |
| Ph+ | 6 (33.3) |
| Therapy before transplantation, n (%) | |
| Median lines of therapy (range) | 2 (1-5) |
| ASPNase-containing regimen | 6 (33.3) |
| Blinatumomab | 8 (44.4) |
| INO | 3 (16.7) |
| CAR T-cell therapy | 2 (11.1) |
| Allo-HCT | 1 (5.6) |
| Disease status before HCT, n (%) | |
| CR1 | 14 (77.8) |
| CR2 | 3 (16.7) |
| CR3 or more | 1 (5.6) |
| HCT-CI, n (%) | |
| 0 | 1 (5.6) |
| 1-2 | 7 (38.9) |
| ≥3 | 10 (55.6) |
| Donor type, n (%) | |
| Matched sibling | 2 (11.1) |
| Haploidentical | 3 (16.7) |
| Matched unrelated | 12 (66.7) |
| Cord blood | 1 (5.6) |
| Donor source, n (%) | |
| Bone marrow | 5 (27.8) |
| Peripheral blood | 12 (66.7) |
| Cord blood | 1 (5.6) |
| Conditioning regimen, n (%) | |
| MAC | 5 (27.8) |
| Busulfan based | 1 (5.6) |
| Other + TBI | 4 (22.2) |
| RIC | 13 (72.2) |
| Busulfan based | 2 (11.1) |
| Melphalan based | 8 (44.4) |
| Other + TBI | 3 (16.7) |
| ATG use | 6 (33.3) |
| GVHD prophylaxis regimen, n (%) | |
| CNI + MTX | 12 (66.7) |
| CNI + MMF | 2 (11.1) |
| PTCy | 4 (22.2) |
| MRD status | |
| MRD+ before HCT | 4 (22.2) |
| MRD+ after HCT | 1 (5.6) |
| MRD+ before and after HCT | 1 (5.6) |
| MRD− either before or after HCT | 12 (66.7) |
ASPNase, asparaginase; ATG, antithymocyte globulin; CAR, chimeric antigen receptor; CNI, calcineurin inhibitor; CR1, first complete remission; CR2, second complete remission; CR3, third complete remission; HCT-CI, HCT-specific comorbidity index; MMF, mycophenolate mofetil; MTX, methotrexate; PTCy, posttransplantation cyclophosphamide; TBI, total body irradiation.
Adverse cytogenetics including BCR/ABL fusion (breakpoint cluster region/Abelson or Philadelphia chromosome), MLL-AF4 (mixed-lineage leukemia- transcription elongation factor 4), MLL (mixed-lineage leukemia) rearrangements, low hypodiploidy, near triploidy, and complex karyotypes.